Features | VJHemOnc

ASH 2023 press briefing rundown: is more or less better? Reviewing therapies in hematologic cancers

VJHemOnc is thrilled to bring you the latest updates from the 65th American Society of Hematology (ASH) Annual Meeting and…

Spotlight On Prolonging Remission In Patients With AML

In this Spotlight On Prolonging Remission In Patients With AML, learn more about the implications of front-line therapy, the role…

Spotlight On Lower-Risk MDS

In this Spotlight On Lower-Risk MDS, learn about risk-stratification & disease classification of MDS, recognizing ESA failure and when to…

FDA grants accelerated approval to talquetamab for patients with R/R multiple myeloma

On August 9, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to talquetamab, a GPRC5DxCD3 bispecific antibody,…

Teclistamab receives positive CHMP opinion for reduced, biweekly dosing schedule in patients with relapsed/refractory multiple myeloma

On July 21, 2023, teclistamab received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…

Talquetamab receives conditional marketing authorization for patients with relapsed/refractory multiple myeloma

On July 21, 2023, talquetamab received conditional marketing authorization (CMA) from the European Medicines Agency’s (EMA) Committee for Medicinal Products…

Trial in Focus: PIMMs – a decentralized trial of ivosidenib in CCUS

VJHemOnc is excited to share a feature on the rationale, design, and aims of the PIMMs trial investigating the use of…

FDA approves quizartinib for newly diagnosed FLT3-ITD AML

On July 20, 2023, the Food and Drug Administration (FDA) approved quizartinib for adult patients diagnosed with newly diagnosed FMS-like…